Understand EAACI 2021 guidelines for anaphylaxis, focusing on clinical criteria and structured training. Read more now!
The NICE guideline on anaphylaxis assessment and referral after emergency treatment provides detailed recommendations for improving care quality. It covers the necessary assessments and referrals to specialist allergy services, emphasizing the importance of prescribing adrenaline injectors before discharge.
The 2023 practice parameter update by the American Academy of Allergy, Asthma & Immunology (AAAAI) focuses on new evidence and recommendations for diagnosing and managing anaphylaxis. It highlights the importance of serum tryptase measurement and specific measures for different community settings.
Hyperkalemia is a common electrolyte disorder observed in the emergency department. It is often associated with underlying predisposing conditions, such as moderate or severe kidney disease, heart failure, diabetes mellitus, or significant tissue trauma.
Adamis Pharmaceuticals Corporation announced that the FDA has approved Adamis� lower dose version (0.15mg) of Symjepi for the emergency treatment...
Adamis Pharmaceuticals Corporation announced that the FDA has accepted for review the Company�s supplemental New Drug Application (�sNDA�) for its...
ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced that the FDA approved neffy (epinephrine nasal spray) 2 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ?30 kg (66 lbs.)
Food allergy encompasses a range of hypersensitivities, with different clinical phenotypes emerging. This review discusses the relevance of these phenotypes for clinical practice and the potential for allergen immunotherapy to modulate them.
FDA approves Neffy epinephrine nasal spray for emergency allergic reactions and anaphylaxis.
ARS Pharmaceuticals, Inc. announced the European Commission's approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms